Piper Jaffray Reiterates Overweight on Inovio Pharma (INO) Following Investor Meetings
Tweet Send to a Friend
Piper Jaffray analyst, Christopher Raymond, reiterated an Overweight rating and $12.00 price target on Inovio Pharmaceuticals (NASDAQ: INO) following investor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
